SOCS1's role in uveal melanoma response to immunotherapy
SOCS1 is a crucial regulator for uveal melanoma response to immunotherapy
This project looks at whether levels of a protein called SOCS1 can predict and help improve immunotherapy response for people with uveal melanoma.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project ID | NIH-11169852 on NIH RePORTER |
What this research studies
Researchers will analyze tumor samples from people with uveal melanoma who received immune checkpoint drugs, measuring SOCS1, MHC molecule levels, and immune cell presence. They will compare samples from patients who responded to treatment versus those who did not and study how changing SOCS1 affects how visible tumor cells are to the immune system using laboratory models. The team aims to link SOCS1 levels to patient survival and treatment response and to identify whether boosting SOCS1 or related pathways could make immunotherapy work better for UM patients.
Who could benefit from this research
Good fit: People with uveal melanoma, especially those with metastatic disease or who are being treated with or considered for immune checkpoint inhibitors, are the ideal candidates.
Not a fit: People without uveal melanoma or those with early localized disease not receiving systemic immunotherapy are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could lead to tests that predict who will benefit from immunotherapy and new ways to boost immunotherapy for uveal melanoma patients.
How similar studies have performed: Immune checkpoint drugs have helped cutaneous melanoma but have shown little benefit in uveal melanoma, and using SOCS1 as a predictive marker or target is a relatively new approach that has not yet been proven in patients.
Where this research is happening
El Paso, United States
- University of Texas El Paso — El Paso, United States (Active)
Researchers
- Principal investigator: Qin, Yong — University of Texas El Paso
- Study coordinator: Qin, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.